Sugi Predict

Sugi Predict / Compounds / SCHEMBL1485098

SCHEMBL1485098

SCHEMBL1485098

CC(C)Oc1ncccc1B1OC(C)(C)C(C)(C)O1

nearest known ligand 0.35

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ LIPE Q05469 4/20 0.35
▸ ALOX5AP P20292 2/20 0.34
▸ FEN1 P39748 2/20 0.34
▸ SLC13A5 Q86YT5 1/20 0.34
▸ LRRK2 Q5S007 1/20 0.33
▸ TRPM8 Q7Z2W7 1/20 0.33
▸ LIPG Q9Y5X9 3/20 0.33
▸ LPL P06858 2/20 0.33
▸ ROCK2 O75116 1/20 0.32
▸ FFAR4 Q5NUL3 2/20 0.32
▸ TRPV4 Q9HBA0 1/20 0.31
▸ MEN1 O00255 1/20 0.31
▸ POLB P06746 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ GRM5 P41594 1/20 0.30
▸ HCRTR1 O43613 1/20 0.30
▸ HCRTR2 O43614 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31441573 1.00 LIPE (0.35) LIPEALOX5APFEN1SLC13A5LRRK2
SCHEMBL18059686 0.87 TRPV4 (0.46) LIPELIPGLPLROCK2TRPV4
SCHEMBL29879003 0.87 TRPV4 (0.46) LIPELIPGLPLROCK2TRPV4
SCHEMBL29140783 0.84 LIPE (0.35) LIPELIPGLPLROCK2TRPV4
SCHEMBL1484864 0.83 APLNR (0.38) LIPELIPGLPLROCK2GRM5
SCHEMBL30292561 0.83 APLNR (0.38) LIPELIPGLPLROCK2GRM5
Water SCHEMBL2513501 0.81 APLNR (0.37) LIPELIPGLPLROCK2GRM5
SCHEMBL365301 0.80 L3MBTL1 (0.36) LIPELIPGLPL
SCHEMBL29900384 0.80 L3MBTL1 (0.36) LIPELIPGLPL
SCHEMBL364666 0.79 LRRK2 (0.35) LRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388599-A1 TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE GENENTECH INC (US) 2025-12-25 — — US disclosed
US-20220348593-A1 TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE GENENTECH, INC. 2022-11-03 — — US disclosed
US-20190330235-A1 TRICYCLIC P13K INHIBITOR COMPOUNDS AND METHODS OF USE GENENTECH INC (US) 2019-10-31 — — US disclosed
EP-2858990-B1 PYRIDINONE AND PYRIDAZINONE DERIVATIVES ABBVIE INC (US) 2018-05-16 — — EP disclosed
US-20170233407-A1 TRICYCLIC P13K INHIBITOR COMPOUNDS AND METHODS OF USE GENENTECH INC (US) 2017-08-17 — — US disclosed
US-9561231-B2 Pyridinone and pyridazinone derivatives ABBVIE INC. (US) 2017-02-07 — — US disclosed
US-9546182-B2 Tricyclic PI3K inhibitor compounds and methods of use GENENTECH, INC. 2017-01-17 — — US disclosed
EP-3053925-A1 TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE F. Hoffmann-La Roche AG (CH) 2016-08-10 — — EP disclosed
EP-2813506-B1 Tricyclic PI3K inhibitor compounds and methods of use HOFFMANN LA ROCHE (CH) 2016-05-25 — — EP disclosed
EP-2483277-B1 BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE HOFFMANN LA ROCHE (CH) 2015-12-02 — — EP disclosed
WO-2013185284-A1 PYRIDINONE AND PYRIDAZINONE DERIVATIVES ABBOTT LABORATORIES (US) 2013-12-19 — — WO disclosed
US-20130331382-A1 Pyridinone and Pyridazinone Derivatives ABBVIE INC. 2013-12-12 — — US disclosed
EP-2651951-A1 TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE F.HOFFMANN-LA ROCHE AG (CH) 2013-10-23 — — EP disclosed
US-20130012488-A1 BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE BLAQUIERE NICOLE (US) 2013-01-10 — — US disclosed
US-8263633-B2 Benzoxepin PI3K inhibitor compounds and methods of use F. HOFFMAN-LA ROCHE AG (CH) 2012-09-11 — — US disclosed
EP-2483277-A1 BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE F. Hoffmann-La Roche AG (CH) 2012-08-08 — — EP disclosed
US-20120171199-A1 TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE NOVOGEN LIMITED (AU) 2012-07-05 — — US disclosed
WO-2012082997-A1 TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE F. HOFFMANN-LA-ROCHE AG (CH) 2012-06-21 — — WO disclosed
WO-2011036284-A1 BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2011-03-31 — — WO disclosed
US-20110076291-A1 BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2011-03-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130012488-A1 BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE PIK3CA, PIK3CD, PIK3R2 LIPE 786/4885ALOX5AP 650/4885FEN1 3049/4885
US-20190330235-A1 TRICYCLIC P13K INHIBITOR COMPOUNDS AND METHODS OF USE PI4KB, PI4KA, PIK3CA LIPE 4272/4885ALOX5AP 4514/4885FEN1 1828/4885
US-20110076291-A1 BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE BMX, NR2E1, NR2E3 LIPE 2677/4885ALOX5AP 2009/4885FEN1 3641/4885
US-20120171199-A1 TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE PIK3CA, PIK3CD, MTOR LIPE 3590/4885ALOX5AP 3844/4885FEN1 2337/4885
US-20170233407-A1 TRICYCLIC P13K INHIBITOR COMPOUNDS AND METHODS OF USE PI4KB, PI4KA, PIK3CA LIPE 4272/4885ALOX5AP 4514/4885FEN1 1828/4885
US-20220348593-A1 TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE PIK3CA, PIK3CD, MTOR LIPE 3590/4885ALOX5AP 3844/4885FEN1 2337/4885
US-20130331382-A1 Pyridinone and Pyridazinone Derivatives CYP4F3, CYP4B1, CYP4F11 LIPE 3086/4885ALOX5AP 629/4885FEN1 3441/4885
US-20250388599-A1 TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE PIK3C2B, PIK3C2A, PIK3R1 LIPE 3957/4885ALOX5AP 4669/4885FEN1 1413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.